AB
Arbutus Biopharma Corp
ABUS · NASDAQ
$4.22 +0.96% (+$0.04)
1M -17.74%
Market Cap $833.6M
P/E Ratio 5.45x
Div. Yield -
ROE 90.98%
Bulios Fair Price
$3.16
25.1% downside
Current Price
$4.22
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ABUS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
5/9Valuation
85 /100
Cheap P/S 4.59x
P/E 5.45x
P/B 3.22x
Growth
0 /100
Declining Book val. growth 17.60%
Rev. growth 28.80%
FCF growth N/A
Profitability
70 /100
Strong Op. margin 81.01%
Gross margin 99.98%
FCF margin 13.55%
Quality
93 /100
Excellent ROA 55.85%
ROIC 54.29%
Asset turnover 0.66x
Debt
100 /100
Low Int. coverage 2,014.87x
Debt/Equity 0.01x
Net debt/EBITDA -0.10x
Stability
47 /100
Moderate EPS volatility 27.12%
Beta 0.62x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ABUS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Lindsay Androski
Employees
19
Headquarters
Warminster
Upcoming events
16 NOV
Earnings
Upcoming earnings report